^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
83P - Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes
Published date:
05/24/2020
Excerpt:
Pts with early-stage HER2+ breast cancer received oral neratinib 240 mg/day or placebo for 12 months (or until disease recurrence or unacceptable toxicity) after trastuzumab-based adjuvant therapy. Patients who receive recommended duration of treatment with neratinib of 12 months may have improved outcomes when compared to patients who discontinue early (within 3 months).
Trial ID:
Source:
Title:
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
Excerpt:
...(Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)...
Trial ID:
Source:
Title:
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Excerpt:
...(Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)...
Trial ID:
Less C2 evidence
Source:
Title:
Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
Published date:
10/09/2021
Excerpt:
N+F+T is a promising combination for pts with HR+, HER2-mutated MBC with prior exposure to CDK4/6 inhibitors. N+T also showed encouraging activity in HER2-mutated TNBC.
Secondary therapy:
fulvestrant
Trial ID:
